World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
60
Citations
15095
World Ranking
3099
National Ranking
178

Gilles Peytavin publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Gilles Peytavin sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 265 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 234 scientists 205–214 publications: 208 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 354 publications — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Gilles Peytavin D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Gilles Peytavin sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 112 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 123 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 94 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 60 D-Index — 44th percentile

44% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Gilles Peytavin is a researcher affiliated with Claude Bernard University Lyon 1 in France, specializing in medicine with a strong focus on infectious diseases. Their work spans several important subfields, including infectious diseases, virology, epidemiology, hepatology, and neurology.

The researcher has made significant contributions to topics including:

  • HIV/AIDS drug development and treatment
  • HIV/AIDS research and interventions
  • HIV research and treatment
  • COVID-19 clinical research studies
  • SARS-CoV-2 and COVID-19 research
  • Hepatitis C virus research
  • Long-term effects of COVID-19

Among their recent publications are:

  • Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial, 2021, The Lancet Infectious Diseases
  • Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon, 2020, The Lancet HIV
  • An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19, 2021, Clinical Microbiology and Infection
  • Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study, 2022, The Lancet HIV
  • Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives, 2020, Clinical Microbiology and Infection

Peytavin frequently collaborates with other researchers in the field. Notable coauthors include Minh Lê, Jade Ghosn, Diane Descamps, Alpha Diallo, and Quentin Le Hingrat.

The bulk of their scientific publications appear in several key venues, such as:

  • Journal of Antimicrobial Chemotherapy
  • Clinical Infectious Diseases
  • Médecine et Maladies Infectieuses Formation
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Microbiology and Infection

The overall body of work indicates a strong research focus on clinical infectious diseases, with particular attention given to viral infections affecting global health, including HIV/AIDS and COVID-19. Their multidisciplinary approach bridges clinical trials, drug resistance studies, and diagnostic marker identification within these domains.

Best Publications

  • On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection

    Abstr Act;C. Capitant;B. Spire;G. Pialoux

  • Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths.

    Paul Bastard;Adrian Gervais;Adrian Gervais;Tom Le Voyer;Tom Le Voyer;Jérémie Rosain;Jérémie Rosain

  • Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy

    D Descamps;P Flandre;V Calvez;G Peytavin

  • Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study

    Jean-Michel Molina;Jean-Michel Molina;Isabelle Charreau;Bruno Spire;Laurent Cotte

  • Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

    Ana Canestri;Franæois-Xavier Lescure;Stephane Jaureguiberry;Antoine Moulignier

  • Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

    Isabelle Malet;Olivier Delelis;Marc-Antoine Valantin;Brigitte Montes

  • Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial

    Christian Laurent;Charles Kouanfack;Sinata Koulla-Shiro;Nathalie Nkoué

  • Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial.

    Jean-Luc Meynard;Muriel Vray;Laurence Morand-Joubert;Esther Race

  • Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C.

    Aude Desnoyer;Dan Pospai;Minh Patrick Lê;Anne Gervais

  • Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

    Christine Katlama;Marc A Valantin;Michele Algarte-Genin;Claudine Duvivier

  • HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report

    Pierre Frange;Pierre Frange;Albert Faye;Véronique Avettand-Fenoël;Véronique Avettand-Fenoël;Erianna Bellaton

  • Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial

    Anani Badje;Raoul Moh;Delphine Gabillard;Calixte Guéhi

  • Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.

    Christophe Piketty;Esther Race;Philippe Castiel;Laurent Belec

  • Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma.

    Anne-Geneviève Marcelin;Roland Tubiana;Sidonie Lambert-Niclot;Gilles Lefebvre

  • Evaluation of the Patient Medication Adherence Questionnaire As a Tool for Self-Reported Adherence Assessment in HIV-Infected Patients on Antiretroviral Regimens

    Michel Duong;Lionel Piroth;Michèle Grappin;Fabien Forte

  • In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

    Delphine Desbois;Bénédicte Roquebert;Gilles Peytavin;Florence Damond

  • HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro

    B. Roquebert;B. Roquebert;F. Damond;G. Collin;S. Matheron

  • Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.

    Jade Ghosn;Marie-Laure Chaix;Gilles Peytavin;Elisabeth Rey

  • Value of Patient Self-Report and Plasma Human Immunodeficiency Virus Protease Inhibitor Level as Markers of Adherence to Antiretroviral Therapy: Relationship to Virologic Response

    Michel Duong;Lionel Piroth;Gilles Peytavin;Fabien Forte

  • Genotypic Inhibitory Quotient as Predictor of Virological Response to Ritonavir-Amprenavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients

    Anne-Geneviève Marcelin;Claire Lamotte;Constance Delaugerre;Nadine Ktorza

  • Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.

    Bénédicte Roquebert;Isabelle Malet;Marc Wirden;Roland Tubiana

Frequent Co-Authors

Christine Katlama
Christine Katlama Sorbonne University
Vincent Calvez
Vincent Calvez Centre national de la recherche scientifique, CNRS
Constance Delaugerre
Constance Delaugerre Université Paris Cité
Françoise Brun-Vézinet
Françoise Brun-Vézinet Université Paris Cité
Anne-Geneviève Marcelin
Anne-Geneviève Marcelin Sorbonne University
Sophie Matheron
Sophie Matheron Université Paris Cité
Jade Ghosn
Jade Ghosn Hôpital Bichat - Claude-Bernard (Hôpitaux Universitaires Paris Nord Val de Seine)
Gilles Pialoux
Gilles Pialoux Tenon Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring microbiology opens doors to diverse career paths, some of which may intersect with other healthcare and scientific fields. For those interested in expanding their expertise, becoming a certified child life specialist salary professional offers a rewarding option that combines science with patient support and advocacy.

Many prospective students may wonder about educational opportunities available despite past challenges. Programs highlighted in what can a felon go to college for provide insight into accessible online degrees, ensuring second chances to those passionate about science and healthcare careers.

For microbiology graduates interested in holistic and integrative healthcare, training to become a functional medicine nurse can broaden clinical skills and promote patient-centered care.

Alternatively, specializing in medical data management through a professional coder certification offers a vital role in the healthcare system with strong job prospects and flexibility.

Each of these pathways complements a foundation in microbiology, offering varied and impactful career options in healthcare and beyond.

Best Scientists Citing Gilles Peytavin

Trending Scientists

Recently Published Articles